CPA
SRNE

Cowen Prime Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Cowen Prime Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,250
Closed -$26K – 313
2015
Q1 		$26K Buy
+2,250
New +$26K 0.01% 212

Other funds holding SRNE

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cowen Prime Advisors's SRNE Position: Q2 2015 in Review

Cowen Prime Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2015, closing a stake of 2,250 shares — an estimated $26K sold.

Cowen Prime Advisors first reported a position in SRNE in Q1 2015 and held it in 1 quarter. The position peaked at $26K in Q1 2015. 75 funds tracked by Wall St. Rank hold SRNE as of Q2 2015.

  • Cowen Prime Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Cowen Prime Advisors sold 2,250 Sorrento Therapeutics, Inc. shares in Q2 2015, an estimated $26K.
  • Cowen Prime Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Cowen Prime Advisors's Sorrento Therapeutics, Inc. position peaked at $26K in Q1 2015.
  • 75 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2015.

Based on Cowen Prime Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.